There are currently no targeted delivery systems to satisfactorily treat bone-related disorders.Many clinical drugs consisting of small organic molecules have a short circulation half-life and do not effectively reach...There are currently no targeted delivery systems to satisfactorily treat bone-related disorders.Many clinical drugs consisting of small organic molecules have a short circulation half-life and do not effectively reach the diseased tissue site.This coupled with repeatedly high dose usage that leads to severe side effects.展开更多
Aluminum adjuvants(Alum),approved by the US Food and Drug Administration,have been extensively used in vaccines containing recombinant antigens,subunits of pathogens,or toxins for almost a century.While Alums typicall...Aluminum adjuvants(Alum),approved by the US Food and Drug Administration,have been extensively used in vaccines containing recombinant antigens,subunits of pathogens,or toxins for almost a century.While Alums typically elicit strong humoral immune responses,their ability to induce cellular and mucosal immunity is limited.As an alternative,layered double hydroxide(LDH),a widely used antacid,has emerged as a novel class of potent nano-aluminum adjuvants(NanoAlum),demonstrating advantageous physicochemical properties,biocompatibility and adjuvanticity in both humoral and cellular immune responses.In this review,we summarize and compare the advantages and disadvantages of Alum and NanoAlum in these properties and their performance as adjuvants.Moreover,we propose the key features for ideal adjuvants and demonstrate that LDH NanoAlum is a promising candidate by sum-marizing its current progress in immunotherapeutic cancer treatments.Finally,we conclude the review by offering our integrated perspectives about the remaining challenges and future directions for NanoAlum's application in preclinical/clinical settings.展开更多
基金financially supported by the National Natural Science Foundation of China (22305117)the Natural Science Foundation of Jiangsu Province (BK20220336)the Natural Science Foundation for Colleges and Universities in Jiangsu Province (22KJB180002)。
文摘There are currently no targeted delivery systems to satisfactorily treat bone-related disorders.Many clinical drugs consisting of small organic molecules have a short circulation half-life and do not effectively reach the diseased tissue site.This coupled with repeatedly high dose usage that leads to severe side effects.
基金European Union's Research and Innovation Program under the Marie Skłodowska-Curie grant agreement(No.101064861)National Natural Science Foundation of China(Nos.32101123,82073782 and 82241002)+1 种基金Guangdong Basic and Applied Basic Research Foundation(No.2022A1515110109,China)Natural Science Foundation of Ningbo(No.2022J273,China).
文摘Aluminum adjuvants(Alum),approved by the US Food and Drug Administration,have been extensively used in vaccines containing recombinant antigens,subunits of pathogens,or toxins for almost a century.While Alums typically elicit strong humoral immune responses,their ability to induce cellular and mucosal immunity is limited.As an alternative,layered double hydroxide(LDH),a widely used antacid,has emerged as a novel class of potent nano-aluminum adjuvants(NanoAlum),demonstrating advantageous physicochemical properties,biocompatibility and adjuvanticity in both humoral and cellular immune responses.In this review,we summarize and compare the advantages and disadvantages of Alum and NanoAlum in these properties and their performance as adjuvants.Moreover,we propose the key features for ideal adjuvants and demonstrate that LDH NanoAlum is a promising candidate by sum-marizing its current progress in immunotherapeutic cancer treatments.Finally,we conclude the review by offering our integrated perspectives about the remaining challenges and future directions for NanoAlum's application in preclinical/clinical settings.
